This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Relationship between percentage (%) glycosylated haemoglobin (HbA1c) and mmol/mol glucose

Authoring team

  • a target HbA1c should be set between 6.5% (48 mmol/mol) and 7.5% (59 mmol/mol) (1)

%

4.0

4.1

4.2

4.3

4.4

4.5

4.6

4.7

4.8.

4.9

mmol/mol

20

21

22

23

25

26

27

28

29

30

%

5.0

5.1

5.2

5.3

5.4

5.5

5.6

5.7

5.8

5.9

mmol/mol

31

32

33

34

36

37

38

39

40

41

%

6.0

6.1

6.2

6.3

6.4

6.5

6.6

6.7

6.8

6.9

mmol/mol

42

43

44

45

46

48

49

50

51

52

%

7.0

7.1

7.2

7.3

7.4

7.5

7.6

7.7

7.8

7.9

mmol/mol

53

54

55

56

57

58

60

61

62

63

%

8.0

8.1

8.2

8.3

8.4

8.5

8.6

8.7

8.8

8.9

mmol/mol

64

65

66

67

68

69

70

72

73

74

%

9.0

9.1

9.2

9.3

9.4

9.5

9.6

9.7

9.8

9.9

mmol/mol

75

76

77

78

79

80

81

83

84

85

%

10.0

10.1

10.2

10.3

10.4

10.5

10.6

10.7

10.8

10.9

mmol/mol

86

87

88

89

90

91

92

93

95

96

%

11.0

11.1

11.2

11.3

11.4

11.5

11.6

11.7

11.8

11.9

mmol/mol

97

98

99

100

101

102

103

104

105

107

%

12.0

12.1

12.2

12.3

12.4

12.5

12.6

12.7

12.8

12.9

mmol/mol

108

109

110

111

112

113

114

115

116

117

%

13.0

13.1

13.2

13.3

13.4

13.5

13.6

13.7

13.8

13.9

mmol/mol

119

120

121

122

123

124

125

126

127

128

Reference:

  • 1) NICE (May 2008). The management of Type 2 Diabetes.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.